RxDoctor Payments Data

Gareth Warren, MD

Urology · Rochester, NYNPI 1710112974

Payments from drug & device makers

$9,506in general payments, 2019–2025

Across 140 payments — averaging $67.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$5K
  • Medtronic$4K
  • Axonics, Inc.$320
  • Valencia Technologies Corporation$139
  • Astellas Pharma US Inc$119
  • Laborie Medical Technologies Corp.$106
  • plus $258 from 5 others

What the payments were for

  • Travel & lodging$3,61938%
  • Food & beverage$5,79961%
  • Education$881%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific53$4,538
Medtronic(2 entities)62$4,026
Axonics, Inc.14$320
Valencia Technologies Corporation1$139
Astellas Pharma US Inc4$119
Laborie Medical Technologies Corp.1$106
Neotract Inc.1$101
Coloplast1$72
Rigicon,inc.1$60
Rochester Medical Corporation1$14
Hologic Sales And Service, LLC1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,506 in reported general payments places this provider in the 75th percentile of 952 urology providers in New York.

See all urology providers in New York

Medicare billing

Part B allowed, 2024
$55,946
Medicare patients
231
Services billed
453

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron50$42,872
GemtesaVibegron43$23,025
Mirabegron ErMirabegron13$5,362
Trospium Chloride ErTrospium Chloride35$3,919
Solifenacin Succinate46$1,618
Oxybutynin Chloride ErOxybutynin Chloride25$641
Finasteride32$540
Tamsulosin Hcl36$445
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst34$400
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip21$166
Cephalexin40$133
Oxybutynin Chloride22$111
Oxycodone Hcl29$48
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim12$23

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$119$42,87250 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 952 urology providers in New York.

Other urology in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →